List of Excipients in Branded Drug TRIAMTERENE HYDROCHLOROTHIAZIDE

Generic Drugs Containing TRIAMTERENE HYDROCHLOROTHIAZIDE

Company	Ingredient	NDC	Excipient
NCS HealthCare of KY Inc dba Vangard Labs	triamterene and hydrochlorothiazide	0615-3583	CELLULOSE, MICROCRYSTALLINE
NCS HealthCare of KY Inc dba Vangard Labs	triamterene and hydrochlorothiazide	0615-3583	CROSCARMELLOSE SODIUM
NCS HealthCare of KY Inc dba Vangard Labs	triamterene and hydrochlorothiazide	0615-3583	D&C YELLOW NO. 10
NCS HealthCare of KY Inc dba Vangard Labs	triamterene and hydrochlorothiazide	0615-3583	FD&C BLUE NO. 1
NCS HealthCare of KY Inc dba Vangard Labs	triamterene and hydrochlorothiazide	0615-3583	HYPROMELLOSE 2910

What are the Most Frequently-Used Excipients in TRIAMTERENE HYDROCHLOROTHIAZIDE?

# Of NDCs	Excipient
5	CELLULOSE, MICROCRYSTALLINE
5	CROSCARMELLOSE SODIUM
5	D&C YELLOW NO. 10
5	FD&C BLUE NO. 1
4	HYPROMELLOSE 2910

Triamterene Hydrochlorothiazide Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Triamterene-hydrochlorothiazide is an established oral diuretic combination with low active-ingredient cost, broad generic competition, and limited regulatory exclusivity. Commercial opportunity is concentrated in formulation quality, dose flexibility, supply reliability, packaging, lifecycle management, and differentiated distribution rather than new-molecule patent protection.

The combination is marketed in the United States primarily as:

• Triamterene 37.5 mg/hydrochlorothiazide 25 mg capsules
• Triamterene 37.5 mg/hydrochlorothiazide 25 mg tablets
• Triamterene 75 mg/hydrochlorothiazide 50 mg tablets

The principal reference products are Dyazide and Maxzide. Triamterene is a potassium-sparing diuretic, while hydrochlorothiazide is a thiazide diuretic. The combination is used to treat hypertension and edema while reducing the potassium loss associated with hydrochlorothiazide alone.

What is triamterene hydrochlorothiazide and how is it formulated?

Triamterene-hydrochlorothiazide is a fixed-dose oral combination. The active ingredients have different physicochemical properties that influence excipient selection and manufacturing design.

Attribute	Triamterene	Hydrochlorothiazide
Drug class	Potassium-sparing diuretic	Thiazide diuretic
Typical combination strengths	37.5 mg or 75 mg	25 mg or 50 mg
Solubility profile	Poorly soluble in water	Slightly soluble in water
Primary formulation concern	Content uniformity and dissolution	Dissolution and blend uniformity
Typical dosage forms	Capsule and tablet	Capsule and tablet
Administration	Oral	Oral

The combination is usually formulated as an immediate-release product. Its low total drug load permits conventional wet granulation, dry granulation, or direct compression, subject to the selected excipient system and manufacturing process.

Common excipient categories include:

• Fillers and diluents, such as lactose, microcrystalline cellulose, starch, or dibasic calcium phosphate
• Binders, such as povidone or pregelatinized starch
• Disintegrants, such as crospovidone, croscarmellose sodium, or sodium starch glycolate
• Glidants, such as colloidal silicon dioxide
• Lubricants, such as magnesium stearate or sodium stearyl fumarate
• Capsule-shell materials, including gelatin, titanium dioxide, and approved colorants
• Film-coating materials for tablet products, including hypromellose, polyethylene glycol, talc, and colorants

Exact excipient composition differs by manufacturer and dosage form. FDA labeling and the FDA Inactive Ingredient Database are the primary sources for product-specific and route-specific excipient analysis.[1,2]

What excipient strategy is most suitable for triamterene hydrochlorothiazide?

A practical excipient strategy should prioritize uniformity, dissolution, manufacturability, and supply continuity. The product does not require a complex delivery platform.

Direct-compression strategy

Direct compression can reduce processing steps and manufacturing cost. A suitable platform may combine:

• Microcrystalline cellulose for compactibility
• Lactose or mannitol for bulk and mouthfeel
• Crospovidone or croscarmellose sodium for rapid disintegration
• Colloidal silicon dioxide for flow
• Magnesium stearate or sodium stearyl fumarate for lubrication

This approach is attractive for high-volume generic manufacturing but requires close control of particle-size distribution, segregation, lubrication time, and blend uniformity. Triamterene's low aqueous solubility makes dissolution performance a central development parameter.

Wet-granulation strategy

Wet granulation can improve content uniformity and reduce segregation, particularly when the active ingredients and excipients have materially different densities or particle sizes. It may be preferable where:

• The drug substances have poor flow
• Low-dose triamterene requires enhanced distribution
• Direct-compression tablets show weight or content-uniformity variability
• A robust dissolution profile is difficult to obtain by direct compression

The process must control granule size, residual moisture, drying temperature, and endpoint determination. Excessive granulation or over-lubrication can delay dissolution.

Dry-granulation strategy

Roller compaction can provide a solvent-free alternative for manufacturers seeking lower water exposure or shorter processing times. It can be useful when:

• Hydrochlorothiazide or triamterene shows moisture sensitivity
• The site seeks a solvent-free process
• Wet granulation causes dissolution or stability problems

The main development risks are ribbon density, fines generation, tabletability, and dissolution after compaction.

Capsule strategy

Capsules offer a relatively simple route to market and can avoid some tablet compression challenges. They may support:

• Faster development
• Lower tablet-capping risk
• Easier color and strength differentiation
• Flexible powder-fill manufacturing

The disadvantages include capsule-shell supply exposure, higher packaging sensitivity to humidity, and potentially less efficient high-speed production than tablets.

What excipients create the strongest commercial differentiation?

Excipient differentiation has limited value if it does not produce measurable product performance or manufacturing benefits. The strongest opportunities are functional rather than cosmetic.

Modified-release or dissolution-control excipients

A modified-release version could create a distinct product profile, but it would require clinical, bioequivalence, and regulatory support. The existing combination is generally positioned as immediate release, so a release-modifying platform would require careful justification of pharmacokinetics, dose delivery, and clinical comparability.

Hydrophilic polymers such as hypromellose, release-controlling matrices, or multiparticulate systems could support a new product concept. This pathway has higher development risk than a conventional generic and may not be commercially justified unless it solves a recognized adherence or tolerability problem.

Taste-masking excipients

Taste masking has limited importance for intact capsules and tablets. It becomes more relevant for:

• Orally disintegrating tablets
• Chewable tablets
• Sprinkle products
• Pediatric formulations
• Extemporaneous suspension alternatives

Triamterene and hydrochlorothiazide are not obvious candidates for a broad over-the-counter taste-masked opportunity because the product remains prescription-controlled and requires renal, electrolyte, and blood-pressure monitoring.

Low-sodium and patient-sensitive formulations

The combination does not generally require sodium-containing excipients. A low-sodium excipient platform could support positioning for patients with dietary sodium restrictions, although the clinical value must be separated from the pharmacologic effects of the product.

Allergen- and intolerance-conscious formulations

A manufacturer may differentiate through:

• Lactose-free formulation
• Gluten-free manufacturing controls
• Dye-free capsules or tablets
• Reduced excipient count
• Gelatin-free capsules using hypromellose

These attributes can support institutional purchasing, pharmacy substitution, and patient preference but usually do not create durable exclusivity unless combined with a patentable formulation or device.

What patents protect triamterene hydrochlorothiazide?

The core active ingredients and legacy fixed-dose combination are generally off-patent products with extensive generic competition. Commercial protection is more likely to arise from product-specific formulation, manufacturing, packaging, or delivery claims than from the active ingredients.

IP category	Commercial relevance
Compound patents	Low for this established combination
Fixed-dose combination patents	Primarily historical
Formulation patents	Possible for novel release, stability, or excipient systems
Method-of-use patents	Limited opportunity for conventional hypertension and edema indications
Manufacturing patents	Possible for improved granulation, uniformity, or impurity control
Packaging patents	Possible for moisture protection or adherence systems
Trademark rights	Relevant to brand names such as Dyazide and Maxzide
Regulatory exclusivity	Generally limited for legacy generic products

Patent analysis should distinguish between expired patents, abandoned applications, unasserted claims, and patents listed in the FDA Orange Book. Patent numbers, expiration dates, and listed uses must be verified in the current Orange Book and relevant USPTO records before investment or launch decisions.[3,4]

When does triamterene hydrochlorothiazide lose exclusivity?

The product has already lost practical market exclusivity in the United States. Generic triamterene-hydrochlorothiazide products are widely available, and the commercial market is driven by abbreviated new drug applications, supplier qualification, manufacturing economics, and payer contracts.

For legacy products, the relevant exclusivity questions are:

1. Whether an applicant has an approved ANDA for the targeted strength and dosage form.
2. Whether the reference product remains commercially available.
3. Whether any Orange Book-listed patent remains active.
4. Whether a product-specific 180-day first-filer period is relevant.
5. Whether state substitution rules permit automatic generic substitution.
6. Whether the manufacturer can meet FDA quality and supply requirements.

A new formulation may obtain protection through a later-filed patent, but a new patent would need to claim a genuine technical distinction. A simple substitution of one conventional filler for another is unlikely to provide strong protection without unexpected performance data.

What is the FDA regulatory status of triamterene hydrochlorothiazide?

Triamterene-hydrochlorothiazide is an FDA-approved prescription drug combination. Generic versions are generally approved through the ANDA pathway by demonstrating pharmaceutical equivalence and bioequivalence to the applicable reference listed drug.

Key regulatory considerations include:

• Strength and dosage-form matching
• Active-ingredient identity and assay
• Content uniformity
• Dissolution testing
• Impurity and degradation-product control
• Stability under ICH conditions
• Container-closure compatibility
• Bioequivalence
• Labeling consistency
• Drug interaction and electrolyte warnings

The combination has clinically important safety considerations involving hyperkalemia, renal impairment, dehydration, and interactions with potassium supplements, potassium-sparing agents, ACE inhibitors, angiotensin receptor blockers, and certain nonsteroidal anti-inflammatory drugs. These risks affect labeling and commercial positioning even when they do not create patent barriers.[5]

What is the Orange Book status of triamterene hydrochlorothiazide?

The Orange Book identifies reference listed drugs, approved generic equivalents, patent listings, and exclusivity information for FDA-approved products. For triamterene-hydrochlorothiazide, the market is predominantly generic and the commercial analysis should focus on the specific strength and dosage form rather than the active ingredients alone.

A capsule approval is not automatically interchangeable with a tablet approval. The following distinctions matter:

• 37.5 mg/25 mg capsule versus 37.5 mg/25 mg tablet
• 75 mg/50 mg tablet versus lower-strength products
• Brand reference product versus generic reference product
• Therapeutic equivalence code
• Current marketing status
• Discontinued or withdrawn products

The Orange Book should be reviewed at the product level before filing a paragraph IV certification or assessing substitution rights.[3]

Are there Paragraph IV challenges for triamterene hydrochlorothiazide?

Paragraph IV litigation risk is generally lower for an established off-patent combination than for a recently approved branded medicine. A paragraph IV certification becomes commercially relevant only when an ANDA applicant challenges an unexpired Orange Book-listed patent.

For a new triamterene-hydrochlorothiazide formulation, the likely patent risks would involve:

• A formulation patent covering a specific excipient ratio
• A dissolution or bioavailability claim
• A manufacturing process
• A multiparticulate or modified-release system
• A stability or impurity-control method
• A packaging system

A conventional generic capsule or tablet would face limited patent risk if no active listed patents cover the reference product. The principal risks would shift to FDA review, bioequivalence failure, product-quality observations, and price competition.

What formulation patents could protect a new product?

Potentially defensible formulation claims would need a technical feature supported by comparative data. Examples include:

• A specific particle-size distribution that improves dissolution
• A defined granulation process that improves content uniformity
• A novel excipient ratio that reduces degradation
• A low-moisture formulation with improved shelf life
• A multiparticulate system with controlled release
• An orally disintegrating product with acceptable taste and dose uniformity
• A fixed-dose combination with demonstrated pharmacokinetic advantages
• A non-gelatin capsule with enhanced humidity stability

The strongest patent position would normally combine composition claims, process claims, and performance data. A single broad excipient claim is more vulnerable to design-around strategies.

What manufacturing and IP barriers affect market entry?

The manufacturing barrier is moderate, not high. The active ingredients are established, but quality execution remains important.

Key barriers include:

• Reliable supply of qualified triamterene and hydrochlorothiazide API
• Control of low-dose triamterene distribution
• Dissolution consistency across scale-up
• Prevention of segregation during blending and transfer
• Lubrication control
• Stability under humidity stress
• Capsule-shell or coating-component supply
• Validation of cleaning procedures
• Control of nitrosamine and other impurity risks where applicable
• Ability to maintain multiple approved manufacturing sites

API sourcing from multiple regions can lower cost but increases qualification, change-control, and regulatory filing burdens. A dual-source strategy is commercially valuable for hospital and wholesaler contracts.

Which companies are competing in triamterene hydrochlorothiazide?

Competition includes branded legacy products, generic manufacturers, contract manufacturers, and distributors. The market is typically fragmented across products sold under manufacturer labels and private-label pharmacy channels.

Competitive variables include:

Variable	Commercial impact
Wholesale acquisition cost	Determines payer and distributor preference
Product availability	Affects substitution and pharmacy retention
Dosage-form breadth	Supports formulary and channel coverage
Packaging configuration	Matters to retail and institutional buyers
Manufacturing redundancy	Reduces shortage risk
Regulatory history	Affects procurement confidence
Capsule or tablet appearance	Supports pharmacy differentiation
Customer service	Important in low-margin generic markets

Relevant competing therapies include hydrochlorothiazide alone, chlorthalidone, indapamide, spironolactone, amiloride-hydrochlorothiazide, and other antihypertensive combinations. The most direct substitution threat is not a biosimilar. It is therapeutic substitution within the diuretic class and generic substitution among equivalent fixed-dose products.

Is there biosimilar risk for triamterene hydrochlorothiazide?

No. Triamterene-hydrochlorothiazide is a small-molecule drug, not a biologic. Biosimilar approval pathways do not apply.

The relevant competition comes from:

• ANDA-approved generics
• Therapeutic alternatives
• Combination antihypertensives
• Hospital and retail private-label products
• Compounded or extemporaneous alternatives in limited settings

What licensing deals and settlement agreements affect the product?

Licensing activity is more likely to involve manufacturing, private-label distribution, API supply, or regional commercialization than core patent licensing. A conventional legacy generic product usually has limited value as a standalone patent-licensing asset.

Potential transaction structures include:

• Authorized generic supply agreements
• Contract manufacturing agreements
• Regional distribution licenses
• Dual-source API agreements
• Private-label pharmacy arrangements
• Portfolio acquisitions involving multiple generic diuretics
• Co-development of a differentiated dosage form

Patent settlement agreements are less likely to be central to the standard immediate-release product because market exclusivity has already eroded. Any settlement involving a newly patented formulation would require review of launch dates, volume restrictions, authorized-generic provisions, and antitrust exposure.

What commercial opportunities exist for triamterene hydrochlorothiazide?

The strongest opportunities are operational and lifecycle-based.

1. Reliable generic supply

Shortage-resistant supply can support premium contracting even in a low-price market. Dual API sources, redundant packaging, and multiple finished-dose sites can improve customer retention.

2. Differentiated packaging

Unit-dose blister packs, calendar packaging, moisture-barrier systems, and adherence-oriented labeling may appeal to institutional and long-term-care channels.

3. Lactose-free, dye-free, or gelatin-free products

These products can address pharmacy preference and patient intolerance. The opportunity is commercial rather than strongly patent-based.

4. Additional dosage forms

Orally disintegrating tablets, smaller tablets, and flexible strengths could address swallowing difficulty and titration needs. These products would require appropriate bioequivalence or clinical support.

5. Private-label portfolios

A manufacturer offering triamterene-hydrochlorothiazide alongside hydrochlorothiazide, amiloride combinations, and other cardiovascular generics can improve contracting economics.

6. International markets

The product has potential in markets where fixed-dose diuretic combinations remain clinically accepted and generic penetration is incomplete. Regulatory requirements, reference-product status, local bioequivalence rules, and price controls vary by jurisdiction.

How strong is the patent estate for triamterene hydrochlorothiazide?

The core patent estate is weak for a conventional immediate-release generic. A new entrant would likely compete on cost, quality, supply, and channel access.

Patent strength would improve only if a sponsor develops:

• A clinically relevant modified-release profile
• A measurable stability advantage
• A novel low-dose uniformity solution
• A differentiated pediatric or dysphagia-friendly product
• A proprietary manufacturing process that is difficult to replicate
• A device or packaging system with independent commercial value

The patent estate should be scored separately from regulatory and manufacturing strength. For this product, manufacturing execution and commercial access are more important than composition-of-matter exclusivity.

What generic launch scenarios exist?

Scenario	Product concept	Market outcome
Low-cost standard generic	Immediate-release capsule or tablet	High price pressure
Supply-reliable generic	Dual-source API and redundant manufacturing	Better institutional positioning
Patient-preference product	Dye-free, lactose-free, or gelatin-free	Niche premium opportunity
Adherence product	Calendar blister or unit-dose package	Channel-specific differentiation
ODT or chewable	Alternative administration	Higher development and regulatory cost
Modified release	New pharmacokinetic profile	Potential IP value, higher clinical risk
Private-label portfolio	Combination with related diuretics	Contracting and distribution advantage

Key Takeaways

• Triamterene-hydrochlorothiazide is an established small-molecule combination with broad generic competition.
• The core active-ingredient patent opportunity is largely exhausted.
• Excipient selection should focus on blend uniformity, dissolution, stability, manufacturability, and supply continuity.
• Direct compression is cost-efficient; wet or dry granulation may improve robustness for low-dose uniformity and dissolution.
• Formulation patents require measurable technical advantages and comparative data.
• Biosimilar risk does not apply.
• Paragraph IV risk is limited for conventional legacy products but can arise for newly patented formulations.
• The most credible commercial opportunities are reliable supply, differentiated packaging, patient-preference excipients, private-label portfolios, and selected alternative dosage forms.
• FDA Orange Book, DailyMed, FDA Inactive Ingredient Database, and USPTO records should govern product-specific patent and excipient decisions.

FAQs About Triamterene Hydrochlorothiazide Excipient and Commercial Strategy

Can triamterene hydrochlorothiazide be formulated as an orally disintegrating tablet?

Yes. An orally disintegrating tablet is technically feasible, but taste, dose uniformity, mechanical strength, disintegration time, and bioequivalence would require focused development.

Which excipient is best for improving dissolution?

No single excipient is universally optimal. Crospovidone, croscarmellose sodium, surfactants, particle-size control, and granulation design can each affect dissolution. The final choice requires comparative formulation and dissolution data.

Is a lactose-free triamterene hydrochlorothiazide product commercially attractive?

It can support pharmacy and patient-preference differentiation, particularly for patients with lactose intolerance. The opportunity is usually niche and depends on pricing, labeling, and distribution access.

Can a new triamterene hydrochlorothiazide product receive orphan-drug exclusivity?

The conventional hypertension and edema indications do not generally fit the orphan-drug framework. A rare-disease strategy would require a distinct qualifying indication and supporting regulatory basis.

Which packaging system best protects the product?

A moisture-barrier bottle or blister system is generally preferable when stability data show sensitivity to humidity. The optimal package depends on the final formulation, closure system, storage conditions, and market channel.

References

1. U.S. Food and Drug Administration. (n.d.). DailyMed: Triamterene and hydrochlorothiazide prescribing information. National Library of Medicine.

2. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/sda/sdIndex.cfm

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda

4. United States Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov

5. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/